Cinctive Capital Management Boosts Biogen Stake by 345%

Hedge fund significantly increases position in biotech company during third quarter

Mar. 15, 2026 at 10:04am

Got story updates? Submit your updates here. ›

Cinctive Capital Management LP grew its stake in Biogen Inc. (NASDAQ:BIIB) by 344.8% in the third quarter, according to a recent SEC filing. The hedge fund now owns 65,837 shares of the biotechnology company's stock, worth $9.2 million as of the latest reporting period.

Why it matters

Biogen is a major player in the biotech industry, particularly in the areas of multiple sclerosis and Alzheimer's disease. Significant changes in ownership by large institutional investors like Cinctive Capital can signal broader market sentiment and future performance expectations for the company's stock.

The details

Cinctive Capital Management increased its Biogen holdings by purchasing an additional 51,035 shares during the third quarter. This represents a 344.8% increase in the firm's position. Other notable investors in Biogen include Banco Bilbao Vizcaya Argentaria, California Public Employees Retirement System, and Alliancebernstein.

  • Cinctive Capital Management reported the increased Biogen stake in its Q3 2026 13F filing with the SEC.

The players

Cinctive Capital Management LP

A hedge fund that significantly increased its position in Biogen Inc. during the third quarter of 2026.

Biogen Inc.

A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

Cinctive Capital's large increase in its Biogen stake suggests the hedge fund sees significant upside potential in the biotech company's stock. This could signal broader market optimism about Biogen's future performance and pipeline.